CRYSTAL LAKE

Aptar Mourns Death of Longtime Board Member, Dr. Joanne Smith

Retrieved on: 
Tuesday, September 7, 2021

AptarGroup, Inc. (NYSE: ATR) today announced with great sadness that Dr. Joanne Smith, a valued longtime member of the Board of Directors, has passed away.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR) today announced with great sadness that Dr. Joanne Smith, a valued longtime member of the Board of Directors, has passed away.
  • View the full release here: https://www.businesswire.com/news/home/20210907005752/en/
    Dr. Joanne Smith, Director and Chairwoman of the Corporate Governance Committee, AptarGroup, Inc. (Photo: Aptar)
    Joanne was a deeply committed member of our Board and a dear friend.
  • Her energy, business acumen and friendship will be missed by all, said George Fotiades, Chairman of the Board.
  • In addition to having served faithfully on Aptars Board since 1999, Dr. Smith was the Chairwoman of the Corporate Governance Committee of the Board.

Aptar Announces the Completion of the Acquisition of a Majority Stake in Voluntis

Retrieved on: 
Thursday, September 2, 2021

The stake acquisition represents approximately 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of 8.70 per share.

Key Points: 
  • The stake acquisition represents approximately 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of 8.70 per share.
  • If the regulatory conditions are met upon completion of the Tender Offer, Aptar intends to implement a squeeze-out on the remaining outstanding shares of Voluntis.
  • This press release contains forward-looking statements, including regarding the potential acquisition of Voluntis and the anticipated effects of the acquisition.
  • Aptar undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Ventegra, Inc. Announces Formation of Nonprofit Public Benefit Corporation – Launch of Ventegra Foundation Aligned With Ventegra’s 100-Year Strategy

Retrieved on: 
Tuesday, August 17, 2021

Dr. Taketomo adds, As a Nonprofit Public Benefit Corporation, Ventegra Foundation will have no obligation to shareholder earnings nor the risk of being flipped into a private equity or venture capital group.

Key Points: 
  • Dr. Taketomo adds, As a Nonprofit Public Benefit Corporation, Ventegra Foundation will have no obligation to shareholder earnings nor the risk of being flipped into a private equity or venture capital group.
  • Ventegra, Inc. is the legacy Ventegra that is dedicated to servicing Ventegra Foundation.
  • www.ventegra.com
    Ventegra Foundation is the new nonprofit Public Benefit Corporation in formation that will be the basis for Ventegra going forward.
  • A complex transition process will be initiated that will transfer the intellectual property and personnel of Ventegra, Inc. into Ventegra Foundation.

Susan W. Green, New Author Releases Debut Novel

Retrieved on: 
Tuesday, August 10, 2021

Her family and friends are always trying to fix her up with an eligible bachelor, but so far, they've been disasters.

Key Points: 
  • Her family and friends are always trying to fix her up with an eligible bachelor, but so far, they've been disasters.
  • Living hours away in New York City, Jack is a reclusive author with a string of books on the best sellers list.
  • Susan W. Green writes contemporary romance novels using lighthearted stories with strong female leads, showing how they overcome challenges and find true happiness.
  • Susan and her husband recently bought a fixer-upper in Maryland and now enjoy peaceful country views.

Aptar Enters into Agreement with Weihai Hengyu Medical Products to Add Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug Delivery

Retrieved on: 
Wednesday, July 28, 2021

This transaction will meet our disciplined investment approach and Hengyus capabilities are complementary to our growing portfolio of injectable solutions.

Key Points: 
  • This transaction will meet our disciplined investment approach and Hengyus capabilities are complementary to our growing portfolio of injectable solutions.
  • Wang Yingye, Co-Founder of Hengyu, stated, Aptar is a world leader in drug delivery solutions.
  • Hengyu shares the same vision as Aptar - to be a drug delivery expert, providing unique, high quality products to the healthcare industry.
  • Located in Weihai, a coastal city in Shandong Province of eastern China, Hengyu designs and manufacturers elastomeric and plastic components used in delivering injectable drugs.

Aptar Announces the Signature of a Share Purchase Agreement Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 Per Share

Retrieved on: 
Friday, July 23, 2021

After and subject to completion of this acquisition, Aptar will launch a mandatory cash tender offer to acquire Voluntis remaining shares for the same price of 8.70 per share (the Tender Offer).

Key Points: 
  • After and subject to completion of this acquisition, Aptar will launch a mandatory cash tender offer to acquire Voluntis remaining shares for the same price of 8.70 per share (the Tender Offer).
  • If the regulatory conditions are met upon completion of the Tender Offer, Aptar intends to implement a squeeze-out on the remaining outstanding shares of Voluntis.
  • This press release contains forward-looking statements, including regarding the potential acquisition of Voluntis and the anticipated effects of the acquisition.
  • Aptar undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aptar Declares Quarterly Dividend

Retrieved on: 
Thursday, July 22, 2021

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today declared a quarterly cash dividend of $0.38 per share.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today declared a quarterly cash dividend of $0.38 per share.
  • As previously announced, Aptar will hold a conference call on Friday, July 30, 2021 at 8:00 a.m. Central Time to discuss the Companys second quarter results for 2021.
  • Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions.
  • Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries.

Aptar Announces Strategic Collaboration with YAT, a Chinese Online Skincare Company, to Develop Range of Products and Services for the Skincare Market

Retrieved on: 
Wednesday, July 7, 2021

Stephan Tanda, Aptar President and CEO, stated, We are pleased to collaborate with YAT to bring new skincare solutions to market.

Key Points: 
  • Stephan Tanda, Aptar President and CEO, stated, We are pleased to collaborate with YAT to bring new skincare solutions to market.
  • Having Aptars resources will bolster our products and services, meeting the increasingly high demands of the market which increasingly also has a sustainability angle.
  • In addition to the partnership, Aptar has made a strategic equity investment in YAT during their latest round of funding.
  • We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics

Retrieved on: 
Tuesday, June 22, 2021

This acquisition would complement Aptars existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases.

Key Points: 
  • This acquisition would complement Aptars existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases.
  • By leveraging Voluntiss platform, Aptar Pharma would be able to develop novel digital therapeutics solutions across multiple disease areas.
  • Pierre Leurent, CEO and co-founder of Voluntis, who would remain in his role post-acquisition, added, We are delighted regarding this possible transaction with Aptar.
  • This press release contains forward-looking statements, including regarding the potential acquisition of Voluntis and the anticipated effects of the acquisition.

Aptar Releases 2020 Corporate Sustainability Report

Retrieved on: 
Thursday, May 27, 2021

The 2020 Sustainability Report highlights Aptars extensive sustainability initiatives that have been implemented across its global operations.

Key Points: 
  • The 2020 Sustainability Report highlights Aptars extensive sustainability initiatives that have been implemented across its global operations.
  • View the full release here: https://www.businesswire.com/news/home/20210527005700/en/
    Aptar's 2020 Corporate Sustainability Report Cover (Graphic: Aptar)
    In 2020, Aptar was recognized with the prestigious A score and named a Supplier Engagement Leader by CDP for actions to cut emissions, mitigate climate risk and further the low-carbon economy.
  • Following the commitment to the United Nations Global Compact in 2020, Aptar is publishing its first UN Global Compact Communication on Progress Report alongside the 2020 Corporate Sustainability Report.
  • The 2020 Sustainability Report is based on the Global Sustainability Reporting (GRI) Standards: Core Options, as released in October 2016.